ODAC Votes against Denosumab to Delay Bone Metastasis in Men with Castration-resistant Prostate Cancer

Get Permission


The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 12 to 1 that the risk-benefit ratio was insufficient for an expanded use of denosumab (Xgeva) to delay the spread of prostate cancer to the bone in men with castration-resistant disease. The panel was not asked specifically whether it recommended approval for this expanded indication. The FDA will make a final decision by April 26, 2012.

According to the panel, the drug’s benefits were outweighed by the possibility of increased toxicity, particularly osteonecrosis of the jaw, with long-term use. The patient representative was the only ODAC panelist to vote in favor of approval for the new indication. ■




By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.